Navigation Links
Inability of Pixantrone to Form Toxic Iron Complexes Results in Significant Reduction in Cardiac Cell Toxicity Compared to Currently Marketed Anthracyclines
Date:12/8/2009

'_blank' title='http://www.CellTherapeutics.com/investors_alert'>http://www.CellTherapeutics.com/investors_alert

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading price of the securities of CTI. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general, and with pixantrone in particular, including, without limitation, the potential failure of pixantrone to prove safe and effective for the treatment of relapsed or refractory, aggressive non-Hodgkin's lymphoma as determined by the U.S. Food and Drug Administration, the potential failure of pixantrone to significantly reduce cardiac cell toxicity compared to currently marketed anthracyclines, the potential failure of pixantrone to reintroduce an effective anthracycline like agent in patients, CTI's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 10-Q and 8-K. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.


Media Contact:
Dan Eramian
T: 206.272.4343
C: 206.854.1200
E: deramian@ctiseattle.com
www.CellTherapeutics.com/press_room

Investors Contact:
Ed Bell
'/>"/>
SOURCE  Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 

Related medicine technology :

1. BD Ranked in the Top 100 Greenest Big Companies by Newsweek; Named Again to Dow Jones Sustainability World and North America Indexes
2. US Oncology, Inc. to Exhibit iKnowMed(TM) at the 2009 ASCO EHR Symposium: Harnessing the EHR: From Incentives to Sustainability
3. 18 month Follow-up Data on Phase III Study of Pixantrone in Late Stage Relapsed or Refractory, Aggressive Non-Hodgkins Lymphoma Continues to Demonstrate Significant Improvement in Complete Remission and Progression Free Survival Over Standard Chemotherap
4. FDA Sets Action Date of April 23, 2010 for Review of Pixantrone NDA
5. Responses After Completion of Therapy Increase Pixantrone Complete Remission (CR)/Unconfirmed Complete Remission (CRu) Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3rd Line Th
6. Overview of Pixantrone Phase III Clinical Data Presentation at American Society of Clinical Oncology 2009 Annual Meeting Now Available at Clinical Care Options
7. Pixantrone in Combination with Chemotherapy Regimens Produces Overall Response Rates of 58-74% with Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL
8. Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment
9. Pixantrone Phase 3 Data to be Presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting
10. Compared to Standard Therapies, Pixantrone Decreases Time to Achieve Complete Remission by 47% in Relapsed Aggressive Non-Hodgkins Lymphoma
11. Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013 Hearing health affects a ... younger, and remain socially and professionally engaged, he should address ... overriding message that the Better Hearing Institute (BHI) ... National Men,s Health Week , which leads up to ... runs from June 10 through June 16. ...
(Date:5/23/2013)... , May 23, 2013  A recently published ... Houston, Texas , demonstrates that 3D ... increasing cancer detection. The study, "Implementation ... Observational Study," was led by Stephen L. ... issue of the American Journal of Roentgenology ...
(Date:5/23/2013)... May 23, 2013  Hadasit Bio-Holdings Ltd. (TASE: HDST, ... companies, based on intellectual property developed and owned ... ,s foremost medical research center, today announced that ... significant funding from the Israeli Ministry of Industry ... to support product development and advance clinical trials. ...
Breaking Medicine Technology:Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 2Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 3Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 4First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams 2First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams 3Hadasit Bio-Holdings Ltd. Portfolio Company - Cell Cure Neurosciences Ltd. Received Additional Government Support 2
... , CAMBRIDGE, Mass., Nov. 19 Ligon Discovery, ... find drugs against high-value targets, today announced that it ... Ventures. The company will use the capital to complete ... high-value disease protein targets. With this investment, incTANK Ventures ...
... , Part of ... Md., Nov. 19 The U.S. Food and Drug ... the International Internet Week of Action (IIWA), intended to ... http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO ) , During the effort, the FDA,s Office ...
Cached Medicine Technology:Cambridge-based Ligon Discovery Raises $1M in Seed Funding 2Cambridge-based Ligon Discovery Raises $1M in Seed Funding 3UPDATE: FDA Issues 22 Warning Letters to Web site Operators 2
(Date:5/23/2013)... Utah (PRWEB) May 23, 2013 Today, ... employer mandate . Zane Benefits, which provides comprehensive ... is the leader in defined contribution plans ... care reform, a common question from employees is “does ... Zane Benefits’ website, not necessarily. The health care reform ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 Onlinefitnessreview.com recently ... Blast Diet to determine what makes this diet work ... published review highlights three main components of the program: ... a positive mindset and the personal motivation that is ... every 7 days to keep the metabolism rate in ...
(Date:5/23/2013)... City, UT (PRWEB) May 23, 2013 ... , a comprehensive radiology learning environment for all ... prebuilt lessons and assessments, transforms the learning experience ... radiology curriculum. , “Until RADPrimer 3.0, ... second to none,” comments Dr. B.J. Manaster, Professor ...
(Date:5/23/2013)... modified version of the polio virus might one ... Scientists at Duke Cancer Institute said the ... engineered form of the virus that is harmless ... therapy shows promise in the treatment of glioblastoma, ... said. "These early results are intriguing," principal ...
(Date:5/23/2013)... Plano, TX (PRWEB) May 23, 2013 ... the Marketplace , Chaplains have been a part of ... this Memorial Day, like those preceding it, these men ... service to the United States of America. As ... trend of their migration to the workplace chaplaincy world. ...
Breaking Medicine News(10 mins):Health News:Zane Benefits Publishes New Information on the Employer Mandate 2Health News:Zane Benefits Publishes New Information on the Employer Mandate 3Health News:Onlinefitnessreview.com Publishes 7 Day Belly Blast Diet Review 2Health News:RADPrimer 3.0 Introduces Comprehensive Radiology Training Curriculum 2Health News:Modified Polio Virus May Help Fight Brain Tumors, Study Suggests 2Health News:Memorial Day Focus Spotlight on Military Chaplains Transitioning in the Marketplace 2Health News:Memorial Day Focus Spotlight on Military Chaplains Transitioning in the Marketplace 3
... technology called the Cone beam computerized tomography (CBCT) is ... complicated oral problems.// ,J. Martin Palomo and ... Case Western Reserve University School of Dental Medicine and ... dental health and biological sciences at the University of ...
... two protein complexes which is found to protect cell ... number of chromosomes leading to cell instability which leads ... research team from Mayo Clinic have found that the ... which maintains the euploidy state in the cell and ...
... Ontario’s hospitals are getting longer, according to Government data which ... the Conservative health critic.// The waiting time rose from 34 ... cancer surgery, while it rose from 139 days to 142 ... days for cardiac surgeries, while in the case of angioplasty, ...
... reported to have been cracked by the researchers from ... treatment of the ailment which causes severe diarrhea,// abdominal ... Dasval. The strain has caused infections to breakout in ... now commence for the other antibiotic resistance genes and ...
... Research Institute (SERI) found that increasing the contrast of ... to the visually impaired. // ,The U.S. study ... to help millions suffering eye diseases. People who may ... macular degeneration, diabetic retinopathy and other causes of low ...
... president of Sandia National Laboratories, Gerry Yonas was the first to ... ,This led to the development of the BiNational Sustainability Laboratory (BNSL), ... Teresa. This will mainly augment the border security force and ... Mexico. ,The monetary inputs for the lab ...
Cached Medicine News:Health News:New Computerized Imaging Systems Help In Better Dental Treatment Planning 2Health News:Visually impaired prefer specially enhanced TV 2Health News:Visually impaired prefer specially enhanced TV 3
... for the quantitative determination of ... kinetic, lag phase of less ... linear phase of at least ... Linearity: 100 mg/dL (35.6 mmol/L ...
For the quantitative determination of direct bilirubin in human serum. Linearity: 20 mg/dl...
... the first microplate spectrophotometer designed specifically to ... per week. With rugged hardware, proven optical ... the barrier of traditional spectrophotometry to obtain ... can easily read up to eight, 1 ...
The PerkinElmer LS 45 Luminescence spectrometer offers versatility, reliability and ease-of-use for routine analyses in an affordable package....
Medicine Products: